Literature DB >> 26038523

Building the Case for Clopidogrel as a World Health Organization Essential Medicine.

Amisha Patel1, Mahesh Vidula2, Sunny P Kishore2, Rajesh Vedanthan2, Mark D Huffman2.   

Abstract

Entities:  

Keywords:  World Health Organization; clopidogrel; drugs; essential

Mesh：

Substances：

Year:  2015        PMID： 26038523      PMCID： PMC4512846          DOI： 10.1161/CIRCOUTCOMES.115.001866

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN： 1941-7713


× No keyword cloud information.
  37 in total

1.  Current status and development of percutaneous coronary intervention in China.

Authors:  Yong Huo
Journal:  J Zhejiang Univ Sci B       Date:  2010-08       Impact factor: 3.066

Review 2.  Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations.

Authors:  William S Weintraub; Leonid Mandel; Sandra A Weiss
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

3.  Polypills: essential medicines for cardiovascular disease secondary prevention?

Authors:  Mark D Huffman; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2014-02-19       Impact factor: 24.094

4.  Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: results from the Kerala acute coronary syndrome registry.

Authors:  Mark D Huffman; Dorairaj Prabhakaran; Adangapuram Kurien Abraham; Mangalath Narayanan Krishnan; Asokan Cheviri Nambiar; Padinhare Purayil Mohanan
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-06-25

5.  Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Anneliese Flynn; Mauro Moscucci; David Share; Dean Smith; Thomas LaLonde; Hameem Changezi; Arthur Riba; Hitinder S Gurm
Journal:  Arch Intern Med       Date:  2010-11-08

6.  Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke, 1999-2011.

Authors:  Harlan M Krumholz; Sharon-Lise T Normand; Yun Wang
Journal:  Circulation       Date:  2014-08-18       Impact factor: 29.690

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 8.  Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events.

Authors:  Ashna D K Bowry; M Alan Brookhart; Niteesh K Choudhry
Journal:  Am J Cardiol       Date:  2008-02-11       Impact factor: 2.778

Review 9.  Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Anne Bellemain-Appaix; Stephen A O'Connor; Johanne Silvain; Michel Cucherat; Farzin Beygui; Olivier Barthélémy; Jean-Philippe Collet; Laurent Jacq; François Bernasconi; Gilles Montalescot
Journal:  JAMA       Date:  2012-12-19       Impact factor: 56.272

Review 10.  Perspective on coronary interventions & cardiac surgeries in India.

Authors:  Upendra Kaul; Vineet Bhatia
Journal:  Indian J Med Res       Date:  2010-11       Impact factor: 2.375
View more
  2 in total

1.  Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial.

Authors:  Diana A Gorog; Mohamed Farag; Nikolaos Spinthakis; Derek M Yellon; Hans Erik Bøtker; Rajesh K Kharbanda; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

Review 2.  The Role of Clopidogrel in 2020: A Reappraisal.

Authors:  Giuseppe Patti; Giuseppe Micieli; Claudio Cimminiello; Leonardo Bolognese
Journal:  Cardiovasc Ther       Date:  2020-03-16       Impact factor: 3.023
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.